FLT3 and acute myeloid leukemia: In vitro data has shown that emavusertib potentiates the antitumor effects of azacitidine in 3 of 4 FLT3-wild type AML cell lines whereas there was no additive or synergistic effect of combining emavusertib with decitabine (95).